Relevium Medical
Relevium Medical is a pharmaceutical company based in Ireland and the US, founded in 2019 as a spin-out from the University of Galway’s BioInnovate Programme, the only European affiliate of Stanford BioDesign. With support from Y Combinator, Enterprise Ireland and the European Innovation Council, the company is developing novel hydrogel-based therapeutics for chronic disorders, leveraging natural biopolymers and active agents for targeted, long-lasting treatment. Relevium has a world-class clinical advisory board and a growing pipeline including products for osteoarthritis, painful bladder, neurogenic bladder, & trauma wound infections. To date the company has secured a total of $8 million non-dilutive funding and private seed investment.
Relevium Medical
Unit 203B, Business Innovation Centre University of Galway Upper Newcastle Galway H91 NY52 Ireland
Relevium Medical is currently seeking investment
Relevium Medical is seeking a series-a investment in the range of 20m-50m
What We Do
An injectable hydrogel designed for intra-articular administration to provide long-lasting pain relief, lubrication, and local delivery for moderate to severe knee osteoarthritis. Developed as a platform that can be extended to other joint conditions.
A hydrogel administered into the bladder to replace the damaged biopolymer lining and suppress sensitised pain nerves in interstitial cystitis.
A multimodal hydrogel for traumatic wounds, formulated with broad-spectrum antimicrobial properties and designed to provide pain relief and infection control.
A hydrogel-based therapy providing long-acting pain relief after surgery, intended to minimise the need for oral analgesics including opioids.